🚀 VC round data is live in beta, check it out!
Medeze Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Medeze Group and similar public comparables like Acumen Pharmaceuticals, Circio Holding, Precision BioSciences, Biomm and more.
Medeze Group Overview
About Medeze Group
Medeze Group PCL is engaged in the business of providing stem cell storage, analyzing, isolation, cultivation and preservation services for medical use. It is organised into four reportable segments: Stem cell sample collection service segment; White blood cell potential testing service segment; Other services segment and Sales of products segment. Geographically, the company operates in Thailand, Vietnam, Cambodia, Philippines, and Other countries, of which maximum revenue is derived from Thailand.
Founded
2010
HQ
Employees
199
Website
Sectors
Financials (LTM)
EV
$153M
Medeze Group Financials
Medeze Group reported last 12-month revenue of $25M and EBITDA of $9M.
In the same LTM period, Medeze Group generated $19M in gross profit, $9M in EBITDA, and $8M in net income.
Revenue (LTM)
Medeze Group P&L
In the most recent fiscal year, Medeze Group reported revenue of $24M and EBITDA of $9M.
Medeze Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $25M | XXX | $24M | XXX | XXX | XXX |
| Gross Profit | $19M | XXX | $17M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $9M | XXX | $9M | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 38% | XXX | XXX | XXX |
| EBIT Margin | 42% | XXX | 36% | XXX | XXX | XXX |
| Net Profit | $8M | XXX | $7M | XXX | XXX | XXX |
| Net Margin | 31% | XXX | 28% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Medeze Group Stock Performance
Medeze Group has current market cap of $205M, and enterprise value of $153M.
Market Cap Evolution
Medeze Group's stock price is $0.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $153M | $205M | 0.0% | XXX | XXX | XXX | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMedeze Group Valuation Multiples
Medeze Group trades at 6.2x EV/Revenue multiple, and 16.3x EV/EBITDA.
EV / Revenue (LTM)
Medeze Group Financial Valuation Multiples
As of April 19, 2026, Medeze Group has market cap of $205M and EV of $153M.
Equity research analysts estimate Medeze Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medeze Group has a P/E ratio of 26.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $205M | XXX | $205M | XXX | XXX | XXX |
| EV (current) | $153M | XXX | $153M | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBITDA | 16.3x | XXX | 17.1x | XXX | XXX | XXX |
| EV/EBIT | 15.0x | XXX | 18.2x | XXX | XXX | XXX |
| EV/Gross Profit | 8.0x | XXX | 9.0x | XXX | XXX | XXX |
| P/E | 26.8x | XXX | 31.3x | XXX | XXX | XXX |
| EV/FCF | (26.1x) | XXX | (287.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Medeze Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Medeze Group Margins & Growth Rates
Medeze Group's revenue in the last 12 month grew by 20%.
Medeze Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Medeze Group's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medeze Group's rule of X is 90% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Medeze Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 57% | XXX | 50% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 66% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 90% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 23% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Medeze Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Medeze Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Acumen Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Circio Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Precision BioSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Biomm | XXX | XXX | XXX | XXX | XXX | XXX |
| Searle Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medeze Group M&A Activity
Medeze Group acquired XXX companies to date.
Last acquisition by Medeze Group was on XXXXXXXX, XXXXX. Medeze Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Medeze Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMedeze Group Investment Activity
Medeze Group invested in XXX companies to date.
Medeze Group made its latest investment on XXXXXXXX, XXXXX. Medeze Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Medeze Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Medeze Group
| When was Medeze Group founded? | Medeze Group was founded in 2010. |
| Where is Medeze Group headquartered? | Medeze Group is headquartered in Thailand. |
| How many employees does Medeze Group have? | As of today, Medeze Group has over 199 employees. |
| Is Medeze Group publicly listed? | Yes, Medeze Group is a public company listed on Stock Exchange of Thailand. |
| What is the stock symbol of Medeze Group? | Medeze Group trades under MEDEZE ticker. |
| When did Medeze Group go public? | Medeze Group went public in 2024. |
| Who are competitors of Medeze Group? | Medeze Group main competitors are Acumen Pharmaceuticals, Circio Holding, Precision BioSciences, Biomm. |
| What is the current market cap of Medeze Group? | Medeze Group's current market cap is $205M. |
| What is the current revenue of Medeze Group? | Medeze Group's last 12 months revenue is $25M. |
| What is the current revenue growth of Medeze Group? | Medeze Group revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Medeze Group? | Current revenue multiple of Medeze Group is 6.2x. |
| Is Medeze Group profitable? | Yes, Medeze Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medeze Group? | Medeze Group's last 12 months EBITDA is $9M. |
| What is Medeze Group's EBITDA margin? | Medeze Group's last 12 months EBITDA margin is 38%. |
| What is the current EV/EBITDA multiple of Medeze Group? | Current EBITDA multiple of Medeze Group is 16.3x. |
| What is the current FCF of Medeze Group? | Medeze Group's last 12 months FCF is ($6M). |
| What is Medeze Group's FCF margin? | Medeze Group's last 12 months FCF margin is (24%). |
| What is the current EV/FCF multiple of Medeze Group? | Current FCF multiple of Medeze Group is (26.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.